Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Nosocomial COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay, in any specimen prior to randomization.~* Admitted to a participating centre~* Is nosocomially acquired infection, as defined by ALL of:~* COVID19 diagnosis being made on admission day three or later;~* Admitted for a reason other than COVID19;~* Within 5 days of COVID19 diagnosis based on test collection date or initial development of symptoms, which ever was earliest.~Exclusion Criteria:~* Plan for palliation within 24 hours~* Known allergy to study medication or its components (non-medicinal ingredients)~* Ordinal scale 6 or above~* Admitted to facility for non-medical reasons including primary psychiatric diagnosis or labour and delivery.~* Pregnancy or breast feeding~* Weight less than 40kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care (Type: NO_INTERVENTION): None
- Anti SARS-CoV-2 monoclonal antibody (Type: EXPERIMENTAL): Single IV administration of an anti-SARS-CoV-2 Monoclonal antibody

Based on this trial design, predict the completion outcome and termination type (if applicable).